Mesothelioma Cancer Centers
Rush University Cancer Center
Doctors Affiliated with this Treatment Facility
The Rush University Cancer Center is part of the non-profit medical group including Rush University Medical Center, Rush University, Rush Oak Park Hospital and Rush Health. The Rush University Medical Center received its charter in 1837 making it the longest running health care institution in Chicago. The charter was reactivated in 1969 to further merge with the Presbyterian-St. Luke’s Medical Center. Rush University itself was established in 1972 and currently consists of the colleges of medicine, nursing, health sciences, and research training. The medical college became Illinois’ first educational facility in medicine.
Rush has been adamant about developing treatments that are innovative and effective. The facility has retained a status of excellence; honored with numerous awards in patient care, education, and research for over 170 years.
All cancer related clinics, programs, research efforts, and educational services are worked on at the Rush University Cancer Center. The academic medical center is committed to an elaborate research program that investigates the most effective treatments and therapies. Extensive outpatient and inpatient centers provide multidisciplinary services. Counseling services are offered as well, providing social and emotional therapy to patients and their families.
The Rush University Cancer Center offers mesothelioma patients care through their lung cancer services department, thoracic surgery department and radiation oncology department. Through their multidisciplinary care approach, the various Rush doctors and nurses working on a patient's case will convene in a single visit to efficiently use a patient’s time and ensure all members of the team are on the same page for treatment and other care needs. The team may include a medical oncologist, thoracic surgeon, radiation oncologist and a nurse coordinator. With this collaborative approach, the Cancer Center is able to provide patients with the comprehensive care needed to fight mesothelioma.
The thoracic surgeons at the Rush University Cancer Center have more experience performing video-assisted thoracoscopic surgery (VATS) than any other surgeons in Chicago. The care team at the center also has expertise in immunotherapy, minimally invasive surgeries, precision medicine and targeted treatments. As an academic medical center, Rush offers patients access to many cutting-edge clinical trials, which delivers the best and newest treatment options to the patients that need them most. Patients receiving care from the lung cancer team also benefit from their partnership with Tempus. The biotechnology company enables patients to have their genetic and clinical data analyzed, allowing for hyper-targeted treatments.
The personalized care at Rush is aimed at supporting patients from diagnosis to treatment and through survivorship.
- Clinical trials
- Minimally invasive surgery
- Precision medicine
- Thoracic surgery
- Video-assisted thoracoscopic surgery (VATS)
- American College of Surgeons Commission on Cancer Accreditation
- Cancer Center ranked as High Performing according to U.S. News & World Reports Best Hospitals report
- Foundation for the Accreditation of Cellular Therapy (FACT) Accreditation
- Joint Commission Accreditation
Mesothelioma Clinical Trials at Rush University Cancer Center
The following clinical trials are in progress or actively recruiting participants at Rush University Cancer Center:
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma Last Updated: July 8, 2019 Status: Recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Conditions: Biphasic Mesothelioma; Epithelioid Mesothelioma; Stage I Pleural Malignant Mesothelioma AJCC v7; Stage IA Pleural Malignant Mesothelioma AJCC v7; Stage IB Pleural Malignant Mesothelioma AJCC v7; Stage II Pleural Malignant Mesothelioma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7 Last Updated: July 4, 2019 Status: Recruiting
Conditions: Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; GIST; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; CNS Tumor; CNS Cancer; Mesothelioma; Breastcancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer Last Updated: November 1, 2018 Status: Recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette